文献速递其他结缔组织病血管炎

阿那白滞素治疗静脉注射免疫球蛋白无反应型川崎病的系统综述

Anakinra for intravenous immunoglobulin-resistant Kawasaki disease: a systematic literature review.
PubMed 文献 · RMD Open · 2026-07-30

该系统综述检索截至2025年10月9日,纳入32篇文献共81例静脉注射免疫球蛋白(IVIG)无反应型川崎病(KD)患者,评估阿那白滞素(ANK)的治疗指征、时机、剂量及疗效安全性。ANK与94.9%患者发热及全身炎症消退相关,冠状动脉瘤(CAA)完全消退占32%、稳定或尺寸缩小占56.3%,未发现严重安全性问题,但证据异质性大且质量低。

要点

  • ANK在IVIG无反应型KD中与94.9%的发热及全身炎症消退相关。
  • CAA完全消退32%、稳定或尺寸缩小56.3%,心脏结局证据有限。
  • 证据异质性大且质量低,需大型随机研究确定最佳时机与剂量。

核心结论

  • 在IVIG无反应型KD中,ANK对控制全身炎症有效,但对冠状动脉结局的疗效仍需更多数据评估。
  • 现有证据鼓励考虑将ANK用于难治性KD,但需大型随机临床研究确定最佳引入时机和剂量并评估长期心脏疗效。

研究设计与样本

  • 系统文献综述,遵循PRISMA 2020指南,检索PubMed、Embase、Web of Science、Cochrane Library、Emcare、Academic Search Premier和Google Scholar从建库至2025年10月9日。
  • 纳入所有报告ANK治疗KD患者结局的研究设计,共纳入32篇文献(数据库检索31篇、交叉引用1篇),描述81例患者。
  • 多数报告为单病例或小系列,含两项早期临床试验。

主要发现

  • ANK治疗与94.9%患者的发热及全身炎症消退相关。
  • CAA完全消退报告于32%的患者,稳定/尺寸缩小报告于56.3%的患者。
  • 未发现严重安全性问题。
  • 上述发现源自异质性大且质量低的证据,应谨慎解读。

关键数值与推荐

  • 约10%-20%的KD患者对IVIG无反应,且发生冠状动脉瘤(CAA)风险增加。
  • ANK治疗与94.9%患者发热及全身炎症消退相关。
  • CAA完全消退占32%,稳定/尺寸缩小占56.3%。

临床怎么用

  • 对于IVIG无反应型KD,ANK可作为控制全身炎症的考虑选项。
  • 使用ANK时需关注冠状动脉结局的随访评估。
  • 最佳治疗时机和剂量尚未确定,需结合个体情况并等待更大规模随机研究证据。

局限性

  • 证据异质性大且质量低,多数为单病例或小系列报告。
  • 仅含两项早期临床试验,样本量小(共81例患者)。
  • 缺乏大型随机临床研究来确定ANK的最佳时机、剂量及长期心脏疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 10%-20% of patients with Kawasaki disease (KD) are resistant to intravenous immunoglobulins (IVIG) and are at increased risk of developing coronary artery aneurysms (CAA). A potential therapeutic role of anakinra (ANK) in refractory KD has been suggested. The aim of this work is to systematically review and critically appraise the available clinical evidence on the use of ANK in the treatment of IVIG-resistant KD, focusing on treatment indications, timing, dosage, efficacy on fever, inflammation, CAA and safety. METHODS: A systematic literature search was conducted across PubMed, Embase, Web of Science, Cochrane Library, Emcare, Academic Search Premier and Google Scholar from inception to 9 October 2025, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Eligible studies included all study designs reporting outcomes of patients with KD treated with ANK. RESULTS: Thirty-two publications (31 identified through database search and one by cross-referencing) describing 81 patients were included. Most reports were single cases or small series, with two early-phase clinical trials. Treatment with ANK was associated with resolution of fever and systemic inflammation in 94.9% of patients. Complete CAA resolution was reported in 32% and stabilisation/dimensional reduction in 56.3%. No serious safety concerns were identified. However, these findings derive from heterogeneous and low-quality evidence and should be interpreted with caution. CONCLUSIONS: In IVIG-resistant KD, ANK was effective in controlling systemic inflammation, although more data are needed to assess its efficacy on coronary outcomes. While these findings are encouraging in supporting consideration of ANK for refractory KD, larger randomised clinical studies are warranted to define optimal ANK timing of introduction and dosing, and to evaluate its long-term efficacy on cardiac outcomes. PROSPERO REGISTRATION NUMBER: CRD420252129435.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Matucci-Cerinic C, Alunno A, Schoones JW, et al. Anakinra for intravenous immunoglobulin-resistant Kawasaki disease: a systematic literature review. RMD Open. 2026. PMID: 42532550. doi:10.1136/rmdopen-2026-006868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。